Remove Bioinformatics Remove Compliance Remove Engineering
article thumbnail

Finding the right CDMO partner for cell line development

Drug Target Review

Finally, comprehensive genetic knowledge also facilitates the use of powerful bioinformatic tools that strengthen the cell-line development process, especially for enhanced protein expression or monoclonality assessment.

article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. chief executive officer of Teneobio.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating the AI revolution: a roadmap for pharma’s future

Drug Target Review

The operational impact of xAI is substantial, especially given that 37 percent of the market views the explanation of results from GenAI algorithms as a strategic priority that goes beyond regulatory compliance. AI adoption will grow, but will require robust infrastructure, pipeline standardisation and training.

article thumbnail

Is That DNA Dangerous?

Codon

And although we can't yet provide a step-by-step compliance guide for the new framework, we can offer insights into how DNA screening algorithms currently work and the difficulties in improving them. And finally, people intent on causing harm could engineer pathogens to become more dangerous. Bioinformatic results from SecureDNA.

DNA 103